News

EMA Starts Safety Review of CAR T-Cell Medicines

January 17, 2024

The agency is reviewing data on secondary malignancies related to T-cells for approved CAR T-cell medicines.

Merck to Acquire Harpoon Therapeutics in Deal Valued at $680 Million

January 16, 2024

Through the acquisition of Harpoon Therapeutics, Merck will gain an investigational delta-like ligand 3-targeting T-cell engager under development for cancer treatment.

Contract Packaging Set for High Growth in 2024

January 16, 2024

According to the Pharmapack Europe 2024 survey results, contract packaging will see growth over the coming 12 months.

AI Biotech Secures Funding to Speed Up Stem Cell Therapy Development

January 16, 2024

CellVoyant has raised £7.6 million in seed funding to speed up the development of novel cell therapies.

Precautionary Measures Recommended in Use of Valproate Medicines

January 15, 2024

The European Medicines Agency safety committee says there is a potential risk of neurodevelopment disorders in children born to men treated with valproate.

Boehringer Ingelheim Expands Facility in Greece for Production of New Therapeutics

January 15, 2024

Boehringer Ingelheim is investing €120 million (US$131 million) into its Koropi, Greece site to expand production for new therapeutics.

Pluri Launches New Cell Therapy CDMO Division

January 11, 2024

Pluri has launched PluriCDMO, a new contract development and manufacturing organization business that will offer cell therapy manufacturing services.

A Platform for mRNA Platforms

January 11, 2024

Regulators from around the world will gather to help shape the mRNA and RNA therapeutics landscape at an exceptional April 2024 Washington, D.C. convocation.

Clarivate Highlights 13 Potential Drugs to Watch in Latest Report

January 10, 2024

Clarivate's Drugs to Watch report highlights 13 potential blockbuster drugs and gamechangers set to launch in 2024.

PharmaKure Gets Nod from MHRA to Trial Drug Targeting Amyloid Deposits

January 10, 2024

MHRA has granted a Clinical Trial Authorization to PharmaKure for its oral combined drug for the treatment of mild cognitive impairment.